Applying the Clinician-reported Genetic testing Utility InDEx (C-GUIDE) to genome sequencing: further evidence of validity

Robin Z. Hayeems 1,2,5, Stephanie Luca 1, Anna C. E. Hurst 3, Meagan Cochran 4, Chelsea Owens 5, Alomgir Hossain 5, Lauren Chad 6,7,8, M. Stephen Meyn 9, Eleanor Pullenayegum 1,10, Wendy J. Ungar 1,2 and David Bick 4,11

© The Author(s) 2022

Genome sequencing (GS) outperforms other rare disease diagnostics, but standardized approaches to assessing its clinical utility are limited. This study assessed the validity of the Clinician-reported Genetic testing Utility InDEx (C-GUIDE), a novel tool for assessing the utility of genetic testing from a clinician’s perspective, for GS. C-GUIDE ratings were completed for patients who received GS results. For each patient, total C-GUIDE and single item global scores were calculated. Construct validity was assessed using linear regression to determine the association between C-GUIDE total and global item scores and measure the effects of potential explanatory variables. Ratings were completed for 67 pediatric and 36 adult patients. GS indications were neurologically for 70.9% and results were diagnostic for 28.2%. When the C-GUIDE assessed primary (PV), secondary (SV), and pharmacogenomic (PGx) variants, on average, a one unit increase in the global item score was associated with an increase of 7.3 in the C-GUIDE score ($p < 0.05$). Diagnostic results were associated with an increase in C-GUIDE score of 5.0 compared to non-diagnostic results ($p < 0.05$) and an increase of one SV was associated with an increase of 2.5 ($p < 0.05$). For children, decreased age of one year was associated with an increase in C-GUIDE score of 0.3 ($p < 0.05$). Findings provide evidence that C-GUIDE measures the construct of clinical utility in pediatric and adult rare disease populations and is sensitive to changes in utility related to variant type. Quantifying the clinical utility of GS using C-GUIDE can inform efforts to optimize its use in patient care.

European Journal of Human Genetics (2022) 30:1423–1431; https://doi.org/10.1038/s41431-022-01192-w

INTRODUCTION

Genetic testing technology is rapidly evolving with the growth of precision medicine. While test evaluation typically relies on laboratory measures of performance (e.g. diagnostic yield) [1], tests can be costly, and analytically and ethically complex [2]. As such, a more comprehensive consideration of value and value for money is warranted to inform clinical adoption [3]. This is particularly true for genome sequencing (GS) where public and private health care systems are specifically seeking evidence of clinical utility to inform decisions about appropriate indications and timepoints for diagnostic testing [4, 5]. They are also adjudicating appropriate use of GS for the identification of secondary and/or pharmacogenomic findings [6–9]. To this end, a growing number of primary studies and evidence syntheses have emerged that report on various dimensions of clinical utility, inclusive of diagnostic, medical management, patient-reported, clinician-perceived, and health economic outcomes of GS [1, 10–13]. While these studies are continuing to better characterize the value and value for money of GS in a range of settings, standardized approaches to measuring the construct of clinical utility remain limited.

The Clinician-reported Genetic testing Utility InDEx (C-GUIDE) was developed to capture the informational value of genetic testing from a clinician’s perspective [14–16]. Specifically, C-GUIDE captures the utility of genetic testing as it relates to: (i) understanding diagnosis and prognosis, (ii) informing medical management, (iii) awareness and actionability of reproductive and health risks for patients and family members, and (iv) patient and family well-being. Modular in format, C-GUIDE items reflect these dimensions of value related to indication-based genetic test results (i.e. primary variants) and test results unrelated to the indication for testing (i.e. secondary and pharmacogenomic variants). A separate single item that reflects the overall value of the genetic test from the clinician’s perspective (i.e. global rating of utility) was also developed for the purpose of assessing C-GUIDE’s construct validity. In its first validation study at The Hospital for Sick Children (SickKids) in Toronto, Ontario, Canada, genetics professionals completed C-GUIDE ratings for 215 patients for whom genetic testing was performed for diagnostic purposes. The sample was largely pediatric and included utility ratings for patients with mostly neurodevelopmental phenotypes who received one of several different genetic test types (i.e. chromosome microarray, single gene, multi-gene panel). Findings indicated that...
an increase in the clinician's global rating of utility was associated with an increase in C-GUIDE total score. In addition, partially/potentially diagnostic and non-diagnostic results had lower C-GUIDE scores than diagnostic results [14]. While these findings provide early evidence that C-GUIDE is a valid measure of clinical utility, significant limitations exist. C-GUIDE modules related to secondary and pharmacogenomic variants and insufficient patients were available to assess its validity in adults. Ongoing assessments of validity in different clinical settings for different types of genetic tests is therefore warranted.

The objective of this study was to assess the construct validity of all modules of C-GUIDE in two US-based tertiary-care genetics settings in which GS—and the reporting of secondary and pharmacogenomic variants—is more widely available.

MATERIALS AND METHODS

Settings

Genetics professionals based at The Smith Family Clinic for Genomic Medicine (SFC), HudsonAlpha Institute for Biotechnology in Huntsville, AL, USA and Children's of Alabama (COA) in Birmingham, AL, USA participated. One genetic counselor completed the C-GUIDE ratings at SFC and one medical geneticist completed the C-GUIDE ratings at COA after disclosing GS results to their patient or their patient's family member. This study received ethics approval from the Institutional Review Boards that oversee SFC and COA (i.e. Western IRB Inc. and The University of Alabama at Birmingham, respectively) as well as the Research Ethics Board at SickKids. Clinician participants reviewed a consent document which indicated that survey completion constituted consent.

Sample and recruitment

With instructions from the study team, clinician raters identified eligible patients, including outpatient visits for whom: (i) GS was completed as part of a diagnostic work up, and (ii) clinically validated positive or negative primary, secondary [17], and/or pharmacogenomic results [18] were reported directly to the patient or family up to two years prior to completing the C-GUIDE rating. Cases ineligible for C-GUIDE ratings included family members of probands who received cascade testing and cases for whom genetic testing was reported prenatally. To receive GS through SFC or COA, cases must have had a chronic medical condition with a likely genetic cause that remained unknown despite thorough evaluation. Candidates for GS were evaluated by a medical geneticist (ACEH at COA, DB at SFC) to ensure GS was an appropriate testing option.

All sequencing was performed at HudsonAlpha's Clinical Services Lab (Huntsville, AL, USA). GS was performed with the Illumina NovaSeq 6000 sequencing platform and all primary, secondary, and complex indel variants were confirmed by Sanger sequencing. With respect to secondary variants, the laboratory reports findings in the following categories: untreatable childhood diseases (e.g., Tay-Sachs), treatable adult-onset diseases (e.g., Lynch syndrome), untreatable adult-onset diseases (e.g., autosomal dominant Alzheimer's disease), and carrier status. As such, not all reported variants are considered to be medically actionable and patients could opt out of receiving them. Based on the reporting criteria used in this laboratory, ~3% of cases are identified to have variants in the American College of Medical Genetics (ACMG) secondary variants gene list (v2.0 [17, 19]) and approximately 33% are identified to have variants in genes related to other treatable conditions (e.g., CHECK2, MTF2, SPINK1, F2, TTR, NOD2). An additional 85% are identified to carry at least one autosomal recessive or X-linked disorder [9]. The pharmacogenomics report is restricted to variants that have been curated by PharmGKB as meeting the highest standard for evidence supporting a variant-drug association (category designated 1A or 1B). All PharmGKB variants in categories 1A or 1B that have dosing guidelines were included in the report except the CYP2D6*5 variant and variants in the HLA-A, HLA-B, and CFTR genes. A stratified recruitment approach was used to include approximately 35 cases for each result type (i.e. diagnostic/partially diagnostic, potentially diagnostic, non-diagnostic) across both sites.

Data collection

Prior to data collection, the study team provided a 60 minute C-GUIDE training session for the clinician raters. C-GUIDE entries were completed between August 2020 and March 2021. For each rated patient, clinicians directly involved in the patient's care completed a Case Description Questionnaire and C-GUIDE (Version 1.1, Supplementary Material) [14] through an online REDCap link [20, 21], using their knowledge of the patient, their own consult notes, or available medical records. Raters were able to start, stop, and resume data entry at their convenience. The Case Description Questionnaire included five items related to the index patient: age, sex, primary indication for testing, number of prior genetic tests, and test urgency and five items related to the test itself: GS strategy, result interpretation, disclosure modality, turnaround time, and time elapsed between result disclosure and C-GUIDE completion. GS strategies included singleton, duo, or trio; trios were defined as cases for whom the index case and two biological relatives received full GS. Result interpretations were defined as pathogenic: diagnostic is a pathogenic/likely pathogenic variant that provides a complete explanation of phenotype; partially diagnostic is a variant of unknown significance that could provide a complete explanation of phenotype OR is a pathogenic/ likely pathogenic variant in a recessive gene without a second hit; and non-diagnostic is a test result that provides no explanation of phenotype.

C-GUIDE includes modules to capture the utility of results related to the primary indication for testing (i.e. primary variants (PV) - 17 items), secondary variants (i.e. SV - 9 items), and pharmacogenomic variants (i.e. PGx - 4 items). Of the 30 C-GUIDE items, 27 are scored from 0 to 2 and three are scored from 2 to 0 using item-specific fixed response options. An item score >0 indicates positive utility, an item score <0 indicates negative utility (“disutility”), and item scores of 0 indicate no utility. For each patient, three different total C-GUIDE scores were calculated (PV only, PV + SV, and PV + SV + PGx) by summing the item scores for each result type [15, 22]. Possible C-GUIDE total scores for each scoring strategy range from −2 to 32 for each PV, −4 to 48 for one PV plus one SV, and −6 to 54 for one PV plus one SV plus one PGx cluster. C-GUIDE is an ordinal scale and items are not weighted.

For the purpose of establishing construct validity of the C-GUIDE score, respondents completed a global rating of utility. This is a single ordinal item that asked raters to select whether, “when taking all results into account” (at the time of disclosure), the test “prompted better care”, “may prompt better care” or “did not change the care provided to the patient or his/her family.” For completion consistency, raters were instructed to define “better care” as a “change in care.” These fixed response options were assigned scores of 2, 1, and 0 respectively.

Analysis

The assessment of construct validity (i.e. the degree to which a test measures what it claims to measure) [23] included three steps: (i) summarizing the case characteristics, (ii) testing hypotheses about the associations between C-GUIDE total scores and clinically important variables, and (iii) verifying relationships between C-GUIDE total scores and the global rating and between C-GUIDE total scores and clinically important variables using a regression model. We summarized patient characteristics and test characteristics with descriptive statistics. Since clinical indication for testing was entered as free text, we developed a categorization scheme to organize these data. Category 1 included neurological indications and category 2 included non-neurological indications. Within category 1, patients were further classified according to the presence or absence of autism spectrum disorder (ASD), attention deficit hyperactivity disorder (ADHD), learning disability (LD), intellectual disability (ID), or developmental delay (DD). Patients in the non-ASD/ADHD/LD/ID/DD category were sub-categorized into five other neurological categories: adult neurological (e.g., neuropathy, spasticity, amyotrophic lateral sclerosis), hypotonia, seizures, hydrocephalus, or other. Within category 2, patients were sub-categorized as: immunological, postural orthostatic tachycardia syndrome (POTS)/dysautonomia, dysmorphic features, hematological, anomalous growth, or other.

Informed by the literature [1, 5, 9, 10, 24], local practice patterns, and study design considerations, we hypothesized that C-GUIDE total scores would rank as follows: (A) diagnostic/partially diagnostic results > potentially diagnostic results > non-diagnostic results; (B) trio GS > singleton GS; (C) pathogenic genetic testing > no prior genetic testing; (D) urgent tests > non-urgent tests; (E) younger patients > older patients; (F) presence of PV > SV > PGx > presence of SV > presence of PV only. To test these hypotheses, a mean C-GUIDE score was calculated within each clinical sub-group defined by relevant patient characteristics. This was repeated for each of the three scoring strategies (PV only, PV + SV, PV + SV + PGx). The mean and range of C-GUIDE scores were
### Table 1. Patient characteristics (*n* = 103).

| Age | Mean (SD) | Range 5 months – 84 years |
|-----|-----------|---------------------------|
| 0–2 years | 22 (21.4) |
| 3–10 years | 29 (28.2) |
| 11–18 years | 16 (15.5) |
| 19+ years | 36 (35.0) |

| Sex | Male | 51 (49.5) |
|-----|------|-----------|
|     | Female | 52 (50.5) |

| Clinical indication for testing | Neurological | ASD/ADHD/LD/ID/DD† | Non-ASD/ADHD/LD/ID/DD | Adult neurological‡ | Hypotonia | Seizures | Hydrocephalus | Other, neurological |
|-------------------------------|---------------|-----------------|---------------------|-----------------|-----------|----------|--------------|------------------|
|                               | 73 (70.9)     | 42 (40.8)       | 31 (30.1)           | 16 (15.5)       | 5 (4.9)   | 4 (3.9)  | 3 (2.9)      | 3 (2.9)           |

| Non-neurological | Immunological | POTS§/Dysautonomia | Dysmorphic features | Dermatological | Hematological | Anomalous growth | Other, non-neurological |
|------------------|---------------|--------------------|---------------------|----------------|--------------|------------------|------------------------|
| 30 (29.1)        | 9 (8.7)       | 6 (5.8)            | 4 (3.9)             | 2 (1.9)        | 2 (1.9)      | 2 (1.9)          | 5 (4.9)                |

| Number of prior genetic tests | 0 | 1 | 2 | >2 | Site** |
|------------------------------|---|---|---|----|-------|
| 19 (18.4)                    | 26 (25.2) | 25 (24.3) | 33 (32) | Site 1 (SFC) |
| 66 (59.2)                    | 35 (35.9) | Site 2 (COA) |

| Test Urgency†† | Urgent | Non-urgent | 101 (98.1) |
|----------------|--------|------------|------------|

| Genome Sequencing (GS) Strategy | Singleton | Duo | Trio |
|---------------------------------|-----------|-----|------|
| 85 (82.5)                       | 5 (4.9)   | 13 (12.6) |

| Clinical interpretation of primary variant (PV1) | Diagnostic/Partially diagnostic | Potentially diagnostic | Non-diagnostic/negative |
|-------------------------------------------------|---------------------------------|-----------------------|-------------------------|
| 29 (28.2)                                        | 38 (36.9)                       | 36 (35.0)             |

| Clinical interpretation of primary variant (PV2) | Diagnostic/Partially diagnostic | Potentially diagnostic | Non-diagnostic/negative |
|-------------------------------------------------|---------------------------------|-----------------------|-------------------------|
| 4 (3.9)                                          | 13 (12.6)                       | 11 (10.7)             |

### Table 1. continued

| All Rated Patients *n* (%) | Clinical interpretation of primary variant (PV3) | Number of secondary variants identified (SV) | Result combinations (PV, SV, PGx) |
|----------------------------|-----------------------------------------------|---------------------------------------------|---------------------------------|
| 29 (28.2)                  | 33 (32.0)                                     | 0                                           | PV only                        |
| 38 (36.9)                  | 31 (30.1)                                     | 1                                           | PV + SV + PGx                  |
| 36 (35.0)                  | 29 (28.2)                                     | 2                                           | Non-diagnostic/negative PV + SV |
|                             |                                               |                                             | Diagnostic/partially diagnostic PV + PGx |
|                             |                                               |                                             | Non-diagnostic/negative PV + PGx  |
|                             |                                               |                                             | Diagnostic/partially diagnostic PV only |
|                             |                                               |                                             | Non-diagnostic/negative PV only   |
|                             |                                               |                                             | Diagnostic/partially diagnostic PV + SV |
|                             |                                               |                                             | Non-diagnostic/negative PV only   |
|                             |                                               |                                             | Diagnostic/partially diagnostic PV only |

| Test turnaround time (TAT; date test ordered to date result disclosed to family) | <4 months | ≥4 months |
|-----------------------------------------------------------------------------|-----------|-----------|
| 66 (59.2)                                                                  | 35 (35.9) |

| C-GUIDE reporting interval (date result disclosed to family to date C-GUIDE completed) | Same day | 1–3 days | 4 days–1 week | >1 week |
|--------------------------------------------------------------------------------|----------|----------|---------------|---------|
| 9 (8.7)                                                                      | 19 (18.4) | 37 (35.9) | 38 (36.9)     |

| Disclosure modality | In person | By phone | Virtually (i.e. video-conference) |
|---------------------|-----------|----------|---------------------------------|
| 70 (68.0)           | 22 (21.4) | 11 (10.7) |

†ASD autism spectrum disorder, ADHD attention deficit hyperactivity disorder, LD learning disability, ID intellectual disability, DD developmental delay.
‡Examples of adult neurological: neuropathy, spasticity, amyotrophic lateral sclerosis (ALS).
§POTS: Postural Orthostatic Tachycardia Syndrome.
**SFC = The Smith Family Clinic for Genomic Medicine, COA = Children’s of Alabama.
††Urgency defined at clinician’s discretion (i.e. related to health state of index case and/or turnaround time).
Table 2. C-GUIDE scores and clinical characteristics.

| Patient age            | Mean PV* C-GUIDE Score (SD) (n = 103) | Mean PV + SV† C-GUIDE Score (SD) (n = 103) | Mean PV + SV + PGx‡ C-GUIDE Score (SD) (n = 103) |
|------------------------|---------------------------------------|-------------------------------------------|---------------------------------------------|
| 0–2 years (n = 22)     | 9.32 (8.40)                           | 13.32 (8.32)**                         | 14.59 (8.29)**                               |
| 3–10 years (n = 29)    | 8.41 (7.32)                           | 12.21 (7.96)                            | 13.52 (8.08)                                |
| 11–18 years (n = 16)   | 2.81 (4.02)                           | 6.38 (5.77)                            | 7.50 (5.93)                                 |
| 19+ years (n = 36)     | 4.14 (5.42)                           | 10.89 (7.73)                            | 11.78 (7.82)                                |
| Patient sex            |                                       |                                           |                                             |
| Male (n = 51)          | 7.49 (7.31)                           | 12.29 (7.86)                            | 13.55 (8.00)                                |
| Female (n = 52)        | 5.02 (6.64)                           | 9.88 (7.79)                            | 10.88 (7.78)                                |
| Clinical indication for testing |                                |                                           |                                             |
| Neurology (n = 73)     | 7.36 (7.50)                           | 11.53 (8.27)                            | 12.67 (8.34)                                |
| Non-neurology (n = 30) | 3.53 (4.99)                           | 9.97 (6.85)                            | 11.07 (6.98)                                |
| Number of prior genetic tests |                                |                                           |                                             |
| 0 (n = 19)             | 5.58 (6.59)                           | 12.16 (8.08)                            | 13.05 (8.17)                                |
| 1 (n = 26)             | 4.92 (6.46)                           | 9.92 (7.21)                            | 11.00 (7.32)                                |
| 2 (n = 25)             | 6.88 (7.40)                           | 10.64 (7.08)                            | 11.92 (7.15)                                |
| >2 (n = 33)            | 7.18 (7.60)                           | 11.70 (8.99)                            | 12.88 (9.08)                                |
| Site                   |                                       |                                           |                                             |
| Site 1 (SFC; n = 70)   | 5.11 (6.66)                           | 10.06 (7.84)**                         | 10.96 (7.89)**†††                           |
| Site 2 (COA; n = 33)   | 8.64 (7.37)                           | 13.24 (7.64)                            | 14.85 (7.58)†                                |
| Test type              |                                       |                                           |                                             |
| Singleton (n = 85)     | 6.39 (7.02)                           | 11.34 (7.39)                            | 12.52 (7.46)                                |
| Duo/Trio (n = 18)      | 5.56 (7.38)                           | 9.83 (10.04)                            | 10.72 (10.16)                               |
| Result type for PV††† (n = # variants) |                                |                                           |                                             |
| Diagnostic or Partially diagnostic (n = 33) | 15.45 (5.67)                          | 20.14 (6.55)***                       | 21.24 (6.59)††††                           |
| Potentially diagnostic (n = 56) | 4.53 (3.11)                         | 9.16 (5.06)                            | 10.34 (5.27)***                             |
| Non-diagnostic (n = 52) | 0.64 (1.85)                          | 5.81 (4.36)                            | 6.89 (4.52)††                              |
| Number of secondary variants identified |                                |                                           |                                             |
| 0 (n = 8)              |                                       | 6.88 (9.79)                             | 7.50 (9.74)                                |
| 1 (n = 13)             |                                       | 6.92 (5.56)***                        | 8.08 (5.55)                                |
| 2 (n = 18)             |                                       | 8.72 (6.64)                            | 9.67 (6.76)                                |
| 3 (n = 19)             |                                       | 11.53 (7.35)                            | 12.74 (7.53)                                |
| 4 (n = 19)             |                                       | 13.84 (8.09)                            | 15.05 (8.00)                                |
| 5 (n = 15)             |                                       | 11.00 (7.24)                            | 12.47 (7.52)                                |
| 6 (n = 7)              |                                       | 18.57 (9.05)                            | 19.57 (9.05)                                |
| 7 (n = 4)              |                                       | 15.50 (5.20)                            | 16.50 (5.20)                                |
| PGx variants (present vs absent) |                                |                                           |                                             |
| Present (n = 98)       |                                       | -                                        | 12.43 (7.80)                                |
| Absent (n = 5)         |                                       | -                                        | 7.80 (10.85)                                |
| Test turnaround time (TAT; date test ordered to date result disclosed to family) |                                |                                           |                                             |
| <4 months (n = 66)     | 6.29 (7.24)                           | 10.79 (7.83)                            | 11.92 (7.93)                                |
| ≥4 months (n = 37)     | 6.16 (6.81)                           | 11.59 (8.05)                            | 12.70 (8.12)                                |
| C-GUIDE reporting interval (date result disclosed to family to date C-GUIDE completed) |                                |                                           |                                             |
| Same day (n = 9)       | 4.67 (5.10)                           | 9.00 (5.50)                             | 10.22 (5.83)                                |
| 1–3 days (n = 19)      | 6.79 (8.22)                           | 10.79 (8.90)                            | 11.95 (9.08)                                |
| 4 days – 1 week (n = 37) | 6.38 (7.14)                         | 11.92 (7.85)                            | 12.97 (7.84)                                |
| >1 week (n = 38)       | 6.24 (7.06)                           | 10.89 (8.02)                            | 12.05 (8.13)                                |
For PV, for 103 rated patients, the total C-GUIDE score ranged from −1 to 26 and the mean score was 6.2 (SD = 7.1). For PV + SV, the total score ranged from −1 to 35 and the mean score was 11.1 (SD = 7.9), and for the combination of PV + SV + PGx, the total score ranged from −1 to 36 and the mean score was 12.2 (SD = 8.0).

Table 2 presents mean C-GUIDE scores according to patient characteristics for each of the three scoring strategies: PV, PV + SV, and PV + SV + PGx. For all three scoring strategies, mean scores were higher among patients for whom diagnostic or partially diagnostic results were received compared to potentially diagnostic results (PV: 15.4 vs. 4.5, p < 0.001; PV + SV: 20.1 vs. 9.2, p < 0.001; PV + SV + PGx: 21.2 vs. 10.3, p < 0.001) or compared to non-diagnostic results (PV: 15.4 vs. 6.0, p < 0.001; PV + SV: 20.1 vs. 5.8, p < 0.001; PV + SV + PGx: 21.2 vs. 6.9, p < 0.001). For all three scoring strategies, mean scores were higher among those who received GS results at COA where all patients were 2–18 years old compared to those who received results by phone (7.2 vs 3.5; p = 0.004; PV + SV: 13.3 vs. 6.4; p = 0.02; PV + SV + PGx: 14.6 vs. 7.5, p = 0.02). Scores were also higher among those who received GS results at COA where all patients were ≤18 years old and 82% had neurological indications for GS, compared to SFC where 51% of cases were ≥19 years and 66% had neurological indications for GS (PV: 8.6 vs 5.1, p = 0.004; PV + SV: 13.2 vs. 10.1, p = 0.03; PV + SV + PGx: 14.8 vs. 11.0, p = 0.01).

For indication-related results only (i.e. PV), mean scores were higher among those with neurological phenotypes compared to those with non-neurological phenotypes (7.4 vs 3.5; p = 0.026), and higher among those who received GS results in-person or virtually compared to those who received results by phone (7.2 vs 2.9; p = 0.05). As expected, for scores related to PV + SV, mean scores were significantly higher among those who received a greater number of SV (PV + SV: 18.6 vs. 6.9; p = 0.04). Across all scoring strategies, mean scores did not differ significantly by sex, number of prior tests, GS strategy, turnaround time, or reporting interval (Table 2).

The global item score reflected the global clinical utility of all results rated per patient (i.e. PV + SV + PGx). Overall, where global item ratings indicated that test results prompted better care (n = 35), the mean C-GUIDE score was 19.6 (SD = 7.2; range: 7 to 36). Where global item ratings indicated that test results may prompt better care (n = 62), the mean C-GUIDE score was 8.5 (SD = 5.4; range: −1 to 26) and where global item ratings indicated that test results did not change care (n = 6), the mean

---

**Table 2. continued**

| Disclosure modality | Mean PV C-GUIDE Score (SD) (n = 103) | Mean PV + SV C-GUIDE Score (SD) (n = 103) | Mean PV + SV + PGx C-GUIDE Score (SD) (n = 103) |
|---------------------|----------------------------------|------------------------------------------|------------------------------------------|
| In person or virtually (i.e., video-conference (n = 81)) | 7.15 (7.35) | 11.95 (8.24) | 13.14 (8.30) |
| By phone (n = 22) | 2.91 (4.64) | 7.86 (5.39) | 8.77 (5.48) |

*PV only = Includes all primary variants (1, 2, 3), as applicable. Mean is over all results.  
PV + SV = Includes all primary and secondary variants, as applicable. Mean is over all results.  
PV + SV + PGx = Includes all primary, secondary and pharmacogenomic variant clusters, as applicable. Mean is over all results.  
Significant difference determined by Kruskal-Wallis, p < 0.001 between variable levels a & c, p < 0.05 and b & c, p < 0.05.  
Significant difference determined by Mann–Whitney, p < 0.05 between variable levels h & i.  
Significant difference determined by Mann–Whitney, p < 0.05 between variable levels J, K & L.  
Significant difference determined by Mann–Whitney, p < 0.05 between variable levels I & M.  
Significant difference determined by Mann–Whitney, p < 0.05 between variable levels N & O.  
Significant difference determined by Mann–Whitney, p < 0.05 between variable levels P & Q, and R & Q, p < 0.001.  
Significant difference determined by Mann–Whitney, p < 0.001 between variable levels S & T, S & U, p < 0.001.  
Significant difference determined by Mann–Whitney, p < 0.05 between variable levels V & W, V & X, p < 0.001.  
Significant difference determined by Mann–Whitney, p < 0.001 between variable levels Y & Z, p < 0.005.  
Significant difference determined by Mann–Whitney, p < 0.005 between variable levels AA & AB.  

---

**RESULTS**

**Characteristics of patients and test results rated by C-GUIDE**

A total of 103 patients were rated; one clinician at SFC completed 70 ratings and one clinician at COA completed 33 ratings (Table 1). For each patient, completing C-GUIDE took 5–10 min of clinicians’ time. A total of 67 pediatric and 36 adult patients were rated (mean age 19.9 years, SD = 21.8). The clinical indication for GS included a neurological phenotype for 70.9%, almost all tests were ordered non-urgently (98.1%), and the majority were singleton (82.5%). Of the rated patients, at least one diagnostic or partially diagnostic variant was identified in 28.2%, at least one potentially diagnostic variant was identified in 36.9%, and non-diagnostic results were reported in 35.0%. SV were identified in 95 patients (92.2%) and PGx were identified in 98 patients (95.1%). In 59.2% of patients, results were reported to the family within four months of testing. In 63.0% of patients, raters completed C-GUIDE within one week of reporting results to the family, and the majority of results were reported in person (68.0%; Table 1). Since only two patients were classified as urgent, this variable was removed from further analyses.
C-GUIDE score was 7.2 (SD = 3.1; range: 2 to 10). The Spearman coefficients of correlation were 0.69 (p < 0.001) for PV only, 0.61 (p < 0.001) for PV + SV, and 0.63 for PV + SV + PGx (p < 0.001).

C-GUIDE score as a function of clinical characteristics

As seen in Table 3, when the C-GUIDE score included only PV (Model 1), on average, a one unit increase in the global item score (i.e. moving from ‘did not prompt’ to ‘may prompt better care’ or from ‘may prompt better to care’ to ‘prompted better care’) was significantly associated with an increase of 6.5 in the C-GUIDE score (p < 0.05). In addition, diagnostic/partially diagnostic/potentially diagnostic results were associated with an increase of 5.5 in the C-GUIDE score compared to non-diagnostic results (p < 0.05).

When the C-GUIDE score included PV + SV (Model 2), on average, a one unit increase in the global item score, representing a change from ‘did not prompt’ to ‘may prompt better care’ or ‘may prompt better to care’ to ‘prompted better care,’ was associated with an increase of 7.1 in the C-GUIDE score (p < 0.05). Across the whole sample, an increase in age of one year was associated with an increase in C-GUIDE score of 0.06 (p < 0.05).

Diagnostic/partially diagnostic/potentially diagnostic results were associated with an increase of 5.0 in the C-GUIDE score compared to non-diagnostic results (p < 0.05), and every additional SV was associated with an increase in C-GUIDE score of 2.4 (p < 0.05).

When the C-GUIDE score included PV + SV + PGx (Model 3), results were similar to Model 2. On average, a one unit increase in the global item score was significantly associated with an increase of 7.3 in the C-GUIDE score (p < 0.05). An increase in age of one year was associated with an increase in C-GUIDE score of 0.07 (p < 0.05), diagnostic/partially diagnostic/potentially diagnostic results were associated with an increase of 5.0 in the C-GUIDE score compared to non-diagnostic results (p < 0.05), and an increase in the number of SV (by one) was associated with an increase in C-GUIDE score of 2.5 (p < 0.05).

Sub-group analyses for children and adults are presented in Table 4a and 4b. For children (≤18 years old), results aligned with the whole sample analyses except that a decrease in age of one year was associated with an increase in C-GUIDE score of 0.2 to 0.3 across the three models (p < 0.05; Table 4a). For adults (>18 years old), results aligned with the whole sample analyses, with the additional findings that an increase in age of one year was associated with an increase in C-GUIDE score of 0.1 for Model 3 (p < 0.05) and every additional prior genetic test was associated with an increase in C-GUIDE score of 1.4 for Model 1 (p < 0.05; Table 4b).

Clinical indication, sex, GS strategy, and site were not independently associated with unit changes in C-GUIDE scores in any of the fitted models.

DISCUSSION

Building on the preliminary validation study for C-GUIDE in Toronto, Canada [14], our findings provide further evidence that C-GUIDE measures the construct of clinical utility from the perspective of clinicians, in pediatric and adult rare disease populations. Specifically, the significant positive association between C-GUIDE total and global item scores in children and adults provides evidence of construct validity. Additional evidence of construct validity is illustrated by our finding that C-GUIDE scores aligned with a priori hypotheses that higher utility would be achieved among those for whom diagnostic results were received compared to those for whom non-diagnostic results were received, and among those for whom SV and PGx were identified compared to those for whom they were not. Moreover, the magnitude of the effects of result type (i.e. diagnostic) and the presence of SV and/or PGx are similar.

In the overall analysis (children and adults combined), when SV and PGx were included in the C-GUIDE score (Table 3 - Models 2, 3), increased age was associated with higher C-GUIDE scores. While some SV indeed have medical management implications (i.e. genetic utility) for children [8], many SV are more likely to be medically actionable in adulthood [29]. Alternatively, where SV reveal carrier status (i.e. in contrast with medically actionable variants), the potential utility of these findings is likely to be greater among individuals who have reached adulthood and may be interested in family planning. While the specific type of SV was not specified for the cases rated by C-GUIDE in this study, ~85% of SV identified by HudsonAlpha’s Laboratory were associated with carrier status [9]. As such, it is reasonable to speculate that the utility of carrier status for family planning provides some explanation for the observed age effect. With respect to PGx, we speculate that the observed increase in C-GUIDE score with age reflects greater use of prescription medication with age [30], thereby increasing the utility of PGx. As expected, a greater number of reported SV and PGx was associated with higher utility scores.

Our sub-group analysis by age refines our interpretation of the observed effect of age. For children alone, we see the effect of age in the opposite direction. That increased age was associated with decreased C-GUIDE scores for all scoring strategies aligns with

| Table 3. Associations between C-GUIDE score, global item score and clinical characteristics (n = 103). |
|---------------------------------------------------------------|
| Variable | Model 1 PV | Model 2 PV + SV | Model 3 PV + SV + PGx |
|-----------|------------|----------------|----------------------|
| Global item score | 6.46* | 7.10* | 7.32* |
| Age | -0.01 | 0.06* | 0.07* |
| Clinical indication | 1.44 | -0.01 | -0.11 |
| Genetic test number | -0.09 | 0.01 | 0.03 |
| Primary variant result type: Diagnostic or Partially Diagnostic or Potentially Diagnostic vs Non-Diagnostic | 5.50* | 5.02* | 4.96* |
| Number of Secondary Variants | 2.38* | 2.48* | 0.6 |
| Sex: Male vs Female | -0.09 | 0.69 | 0.71 |
| GS Strategy: Singleton vs Duo/Trio | 0.26 | 1.07 | 1.09 |
| Site | 0.93 | 1.47 | 2.11 |
| Goodness-of-fit statistics: Adjusted R-square | 59% | 53% | 56% |

*p < 0.05.

†HCC heteroscedasticity-consistent standard errors.
arguments in the literature that favour the use of GS as early as possible in the diagnostic journey for patients with rare disease [24, 31, 32]. We speculate that for children, the utility of a timely diagnosis trumps the utility of SV and PGx. Interestingly, for adults, we observed that the receipt of prior genetic testing was positively associated with C-GUIDE scores, perhaps suggesting that it is for children. Finally, the absence of an observed effect for clinical indication, sex, and GS strategy suggests that the utility of GS results is independent of these factors.

The mean and range of C-GUIDE scores associated with each global item response option were similar to those reported in the Toronto validation study [14]. As expected, C-GUIDE scores in the present study were higher among patients with the highest global rating and lower among patients with the lowest global rating. While C-GUIDE and global scores are moderately correlated (r = 0.61–0.69), C-GUIDE ranges for each global item category overlapped, suggesting that more work is required to establish the clinical meaning of various C-GUIDE scores as well as population norms and thresholds for high and low utility ratings for different categories of variants. As discussed in the first C-GUIDE validation study, as the list of reportable PV, SV and PGx expands and as variant interpretations change with an evolving knowledge base, C-GUIDE scores, and their clinical meaning, will evolve [14].

We acknowledge limitations related to this assessment of construct validity. First, small numbers of patients were enrolled for some categories of clinical characteristics. As such, hypotheses regarding the effects of these characteristics on C-GUIDE score could not be tested. For example, the low rate of urgent patients (i.e. 2%) precluded our ability to assess the hypothesis that greater clinical utility would be achieved for urgent testing compared to non-urgent testing. Second, small sample size precluded the assessment of plausible interactions. Third, while sub-group analyses by age demonstrated construct validity in both children and adults and refined our interpretation of the observed age effect, further validity testing in adults is warranted given the small number of adults included. Fourth, while we were able to demonstrate construct validity related to SV and PGx, we could not differentiate the utility of medically actionable versus non-medically actionable SV since raters were not asked to characterize the type(s) of SV identified. Finally, ratings provided for the retrospective cases at SFC reflect the content of the clinician’s consult note that was written up to two years prior to C-GUIDE completion, rather than the perspective of the clinician at the time of result disclosure. To what extent real-time versus retrospective assessments of utility differ warrants further study.

Validating C-GUIDE in a clinical setting that is external to the environment in which it was developed further demonstrates its credibility and generalizability as an empiric universal strategy for measuring the value of genetic testing, as perceived by clinicians. Moreover, the application of C-GUIDE to the context of GS enabled
us to assess its validity for SV and PGx, an emerging area of practice that warrants robust approaches to evidence development. Further work to validate its use among non-genetics providers, to understand if/how utility ratings change over time, and how patients orient to the concept of utility is ongoing. In conclusion, our findings suggest that C-GUIDE achieves acceptable levels of construct validity and can be integrated into studies that aim to capture the clinical utility of a broad range of genetic tests used for the purpose of establishing a genetic diagnosis in children and adults. Quantifying clinical utility in standardized ways will inform efforts to optimize the use of genetic and genomic technologies in patient care and provides key evidence for funding and adoption decisions.

DATA AVAILABILITY
All data generated or analyzed during this study are either included in this published article or available upon request.

REFERENCES
1. Clark MM, Stark Z, Farnaes L, Tan TY, White SM, Dimmock D, et al. Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases. NPJ Genom Med. 2018;3:316.
2. Faulkner E, Holfort A-P, Walton S, Liu CY, Lin H, Biltaj E, et al. Being precise about precision medicine: what should value frameworks incorporate to address precision medicine? A report of the personalized precision medicine special interest group. Value Health. 2020;23:529–39.
3. Hayeems RZ, Dimmock D, Bick D, Belmont JW, Green RC, Lanpher B, et al. Clinical utility of genomic testing: a measurement toolkit. NPJ Genom Med. 2020;5:56.
4. Li C, Vandersluis S, Holubowich C, Ungar WJ, Goh ES, Boycott KM, et al. Cost-effectiveness of genome-wide sequencing for unexplained developmental disabilities and multiple congenital anomalies. Genet Med. 2021;23:451–60.
5. Ontario Health Quality. Genome-wide sequencing for unexplained developmental disabilities or multiple congenital anomalies: a health technology assessment 2020. Available from: https://www.hqontario.ca/Portals/0/Documents/evidence/reports/hta-genome-wide-sequencing.pdf.
6. Black WC, Welch HG. Screening for disease. AJR Am J Roentgenol. 1997;168:3 1–8.
7. de Wert G, Dondrop W, Clarke A, Dequeker EMC, Cordier C, Deans Z, et al. The construct of clinical utility in the context of genetic testing: a scoping review. Hum Genet. 2021;140:1403–14.
8. Richer J, Laberge A-M. Secondary findings from next-generation sequencing: what does actionable in childhood really mean? Genet Med. 2019;21:124–32.
9. Cochrane M, East K, Greve V, Kelly M, Kelley W, Moore T, et al. A study of elective genome sequencing and pharmacogenomic testing in an unselected population. Molecular Genetics & Genomic Medicine. 2021;9:e1766.
10. Chipchick H, Bright K, Urquhart E, Pechlivanoglou P, Bombard Y. The clinical utility of exome and genome sequencing across clinical indications: a systematic review. Hum Genet. 2021;140:1403–14.
11. Mccourt C, Shick S, Elyeik Y, Peclivanoglou P, Bombard Y. Clinical and psychological outcomes of receiving a variant of uncertain significance from multigene panel testing or genomic sequencing: a systematic review and meta-analysis. Genet Med. 2021;23:22–33.
12. Walcott SE, Miller FA, Dunsmore K, Lazor T, Feldman BM, Hayeems RZ. Measuring the construct of clinical utility in the context of genetic testing: a scoping review. Eur J Hum Genet. 2021;29:378–86.
13. Schwarze K, Buchanan J, Taylor JC, Wordsworth S. Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature. Genet Med. 2018;20:1122–30.
14. Hayeems R, Luca S, Venkataramanan V, Triploka K, Bashir NS, Chad L, et al. The Clinician-reported Genetic testing Utility InDex (C-GUIDE): Preliminary evidence of validity and reliability. Genet Med. 2022;24:430–8.
15. Hayeems RZ, Luca S, Ungar WJ, Bhattacharya A, Chad L, Pullenayegum E, et al. The development of the Clinician-reported Genetic testing Utility InDex (C-GUIDE): a novel strategy for measuring the clinical utility of genetic testing. Genet Med. 2020;22:95–101.
16. Hayeems RZ, Luca S, Pullenayegum E, Meyn MS, Ungar WJ. Genome diagnostics: novel strategies for measuring value. J Manag Care Spec Pharm. 2019;25:1096–101.
17. Kalia SS, Adelman K, Bale SJ, Chung WK, Eng C, Evans JP, et al. Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19:249–55.
18. Cohn L, Paton TA, Marshall CR, Basran R, Stavropoulos DJ, Ray PN, et al. Genome sequencing as a platform for pharmacogenomic genotyping: a pediatric cohort study. NPJ Genom Med. 2017;2:19.
19. CORRIGENDUM: Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics. Genet Med. 2017;19:484.
20. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.
21. Harris PA, Taylor R, Thieleke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) – a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377–81.
22. de Vet HCW, Tenwee CB, Mokkink LB, Knol DL. Measurement in medicine: a practical guide. Cambridge: Cambridge University Press; 2011.
23. Cronbach LJ, Meehl PE. Construct validity in psychological tests. Psychological Bull. 1955;52:281–302.
24. Kingsmore SF, Cakici JA, Clark MM, Gaughran M, Feddock M, Batalov S, et al. A Randomized, controlled trial of the analytic and diagnostic performance of singleton trio, rapid genome and exome sequencing in 3 Ill infants. Am J Hum Genet. 2019;105:719–33.
25. Hayeems RZ. The Clinician-reported Genetic testing Utility InDex (C-GUIDE) User Manual & Interpretation Guide 2021. Available from: https://labresearch.sickkids.ca/hayeems/wp-content/uploads/sites/70/2022/01/C-GUIDE-User-Manual_FINAL.pdf.
26. IBMB Corp. IBM SPSS Statistics for Windows, Version 27.0. Armonk, NY: IBM Corp; Released 2020.
27. Long JS, Ervin LH. Using heteroscedasticity consistent standard errors in the linear regression model. Am Statistician. 2000;54:217–24.
28. SAS Institute Inc. SAS 9.4. Cary, NC, USA: SAS Institute Inc.
29. Miller DT, Lee K, Chung WK, Gordon AS, Herman GE, Klein TE, et al. ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2021.
30. Martin CB, Hales CM, Gu Q, Ogden CL. Prescription drug use in the United States, 2015–2016. NCHS Data Brief, no 334 2019. Available from: https://www.cdc.gov/nchs/products/databriefs/db334.htm.
31. Friedman JM, Bombard Y, Cornel MC, Fernandez CV, Junker AK, Plon SE, et al. Genome-wide sequencing in acutely ill infants: genomic medicine’s critical application? Genet Med: Off J Am Coll Med Genet. 2019;21:498–504.
32. Tan TY, Dillon OJ, Stark Z, Schofield D, Alam K, Shrestha R, et al. Diagnostic impact and cost-effectiveness of whole-exome sequencing for ambulant children with suspected monogenic conditions. JAMA Pediatr. 2017;171:855–62.

ACKNOWLEDGEMENTS
We would like to thank The Children’s of Alabama Board of Trustees for funding the Children’s of Alabama Genome Sequencing study and patients and families for participating in genome sequencing.

AUTHOR CONTRIBUTIONS
RH, SL, ACEH, MC, LC, MSM, WU, DB contributed to study conceptualization and methodology. ACEH, MC, CO and DB collected the study data. RH, SL, AH, EF, and WU conceptualized the data analysis plan. SL and AH conducted the data analysis. SL was responsible for project administration. RH drafted the paper and all authors reviewed and edited the paper.

FUNDING
This work was funded by the Canadian Institutes of Health Research Project Grant (PJT-152880). Robin Z. Hayeems is supported by the Canada Research Chair in Genomics and Health Policy (Tier 2). Wendy J. Ungar is supported by the Canada Research Chair in Economic Evaluation and Technology Assessment in Child Health.

COMPETING INTERESTS
The authors declare no competing interests.

ETHICS APPROVAL
This study received ethics approval from the Institutional Review Boards that oversee SFC and COA (i.e. Western IRB Inc. and The University of
Alabama at Birmingham, respectively) as well as the Research Ethics Board at SickKids.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41431-022-01192-w.

Correspondence and requests for materials should be addressed to Robin Z. Hayeems.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.